Raffles Medical Group Ltd
RAFLF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 9.90 | 0.00 | 4.98 |
| FCF Yield | 1.52% | 1.80% | 1.30% | 1.42% |
| EV / EBITDA | 48.72 | 40.08 | 52.50 | 47.28 |
| Quality | ||||
| ROIC | 1.36% | 1.36% | 1.27% | 1.27% |
| Gross Margin | 45.95% | 45.95% | 45.19% | 45.19% |
| Cash Conversion Ratio | 1.76 | 1.76 | 1.64 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.89% | -8.26% | -9.12% | -14.76% |
| Free Cash Flow Growth | 0.00% | 21.90% | 0.00% | 92.66% |
| Safety | ||||
| Net Debt / EBITDA | -8.03 | -7.88 | -9.28 | -9.12 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 9.07 | 9.07 | 9.85 | 9.85 |
| Cash Conversion Cycle | -95.10 | -95.10 | -101.03 | -101.03 |